Lion TCR
Singapore’s Lion TCR secures $40M in Series B2 financing led by Chinese investors
Lion TCR, a Singapore-based clinical-stage T-cell immunotherapy company, has announced the successful completion of its $40 million Series B2 financing round. Guangzhou Industrial Investment and Capital Operation Holding Group Ltd. led the financing with participation from Guangzhou Guoju Investment and CSPC NARD Capital Fund.
